frontiers in Molecular Biosciences

CORRECTION
published: 18 November 2016
doi: 10.3389/fmolb.2016.00075

Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models

*Roberta Coroniti[1], Rafal Farjo[2], Didier J. Nuno[2], Laszlo Otvos[3], Laura Scolaro[1] and Eva Surmacz[1]**

[1] Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA , [2] Department of Biology, Temple University, Philadelphia, PA, USA, [3] EyeCRO, Oklahoma, OK, USA

Keywords: leptin, ObR antagonist, peptide drug, VEGF, ocular neoangiogenesis

Edited and reviewed by:
Ali Tavassoli,
University of Southampton, UK

****Correspondence:***
Eva Surmacz
surmacz@temple.edu

Specialty section:
This article was submitted to Chemical Biology, a section of the journal Frontiers in Molecular Biosciences

Received: *26 October 2016*
Accepted: *31 October 2016*
Published: *18 November 2016*

Citation:
Coroniti R, Farjo R, Nuno DJ, Otvos L, Scolaro L and Surmacz E (2016) Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models. Front. Mol. Biosci. 3:75. doi: 10.3389/fmolb.2016.00075

A corrigendum on

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models

by Coroniti, R., Farjo, R., Nuno, D. J., Otvos, L., Scolaro, L., and Surmacz, E. (2016). Front. Mol. Biosci. 3:67. doi: 10.3389/fmolb.2016.00067

In the original article, the name of the author Rafal Farjo was misspelled as Rafal Fario.

The correct spelling appears above. The authors apologize for this error. This does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.